Regeneron's Ebola Antibody Maftivimab Recommended by WHO for Clinical Trials

The World Health Organization on May 29, 2026, recommended Regeneron Pharmaceuticals' (NASDAQ: REGN) antibody maftivimab for inclusion in Ebola virus disease clinical trials, a decision that could accelerate development of a targeted treatment. The WHO's Strategic Advisory Group of Experts on Immunization issued the guidance, citing the need for expanded therapeutic options against the often-fatal hemorrhagic fever. Maftivimab is an investigational monoclonal antibody designed to neutralize the Zaire ebolavirus. The endorsement may ease trial authorizations and attract further funding. Regeneron shares moved modestly higher in pre-market trading following the announcement. The company previously gained emergency-use authorization for its COVID-19 antibody cocktail and developed Inmazeb, an approved three-antibody Ebola regimen that includes maftivimab. The WHO recommendation is expected to spur late-stage testing and could eventually reshape standard Ebola care protocols.